Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treat
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... Feb. 8, 2011 The District of Columbia Patients Cooperative ... to provide high quality and affordable medical "marijuana" to qualifying ... implementation of DC,s new medical marijuana program.  The public meeting ... place on Thursday, February 10th at 7:00 pm in Pierce ...
... TUCSON, Ariz., Feb. 8, 2011 MRI Medical Inc. ... as part of its corporate development plan. ... provide our customers with the same superior design, development, ... years," stated Joseph Lee, Xeridiem Medical Devices, Inc.,s President. "Our ...
Cached Medicine Technology:February 10 Town Hall Meeting to Explain DC's New Medical Marijuana Program 2MRI Medical Inc. Changing Name to Xeridiem Medical Devices, Inc. 2
(Date:7/13/2014)... a well-known casket manufacturer from China, has announced its newest ... executive officer has announced a new promotion for its funeral ... prices, from 15 to 26 percent off. , “As far ... in the current market. We are excited to release the ... high quality products for sale. Many of our clients are ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... 2014 Fuel additives are chemicals, which ... jet fuel, kerosene, and so on, in order to ... reducing the corrosion effects caused by fuels and improving ... any fuel, provide economies of scale in the long ... overall cost of the fuel products. , The various ...
(Date:7/13/2014)... New York, New York (PRWEB) July 13, 2014 ... much to bring attention to the cancer risks associated ... a chance to tell their story to federal regulators, ... of a U.S. Food & Drug Administration (FDA) ... Liebhard LLP reports. According to the Rochester Democrat ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... ST. LOUIS: Following Advanced Medical Optics' voluntary recall ... lens solution, doctors of optometry from the ... Section concur with the company's decision to remove ... has not been officially determined, health officials from ...
... Biochemical Zoology, a fascinating new selection of papers ... selection, providing insight into how organisms adapt ... ,Dr. James Hicks, Editor in Chief of PBZ, ... "This exciting approach experimental evolution allows ...
... against the myriad strains of the human immunodeficiency virus ... study conducted at the Uniformed Services University of the ... extremely variable, its prevention requires a vaccine effective enough ... can neutralise multiple viral strains. ,The ...
... new study has found that being exposed to pesticides, as ... of developing Parkinsons. ,The study, which is published ... Medicine, one of the BMJ Specialty Journals, states that the ... ,959 people suffering with Parkinsons, as well as 1,989 controls ...
... new research has found that HIV and malaria combine ... ,University of Toronto researchers have exposed the ... and have also discovered how the HIV virus works ... superior vaccines for pregnant women in malaria-ravished regions. ...
... Early data for an investigational device that specifically targets ... , called Tumor-Treating Fields (TTFields), has found that it ... patients with the most common and aggressive type of ... Novo-TTF, uses electrical fields to disrupt tumor growth by ...
Cached Medicine News:Health News:Optometrists Support AMO's Voluntary Contact Lens Solution Recall 2Health News:Research Throws Light on Adaptation of E.coli to Changing Conditions 2Health News:Risk of Parkinsons Increased by Exposure to Pesticide and Head Trauma 2Health News:Malaria and HIV Jointly Affects Pregnant Women and Their Infants 2Health News:Device That Targets Brain Cancer Shows Promising Results 2
... is designed to augment areas ... midface, including the inferior orbital ... in the hollow under the ... implant aids in restoring the ...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Medicine Products: